UroGen Pharma (URGN) opened 2026 with Q1 revenue of US$51.0 million and a basic EPS loss of US$0.47, alongside a net income loss of US$23.6 million, setting a clear marker for how the business is scaling while remaining loss making. The company has seen quarterly revenue move from US$20.3 million in Q1 2025 to US$51.0 million in Q1 2026, while basic EPS over that span ranged from a loss of US$1.05 in Q2 2025 to a loss of US$0.47 in the latest quarter. As a result, investors are getting a clearer view of how growing sales are interacting with still negative margins.

See our full analysis for UroGen Pharma.

With the headline numbers on the table, the next step is to set these results against the main narratives around growth, risk, and profitability to see which stories the latest quarter supports and which it challenges.

Losses Narrow On Higher TTM Revenue Base

• On a trailing twelve month basis, revenue sits at US$140.5 million with a net loss of US$133.2 million, compared with quarterly Q1 2026 figures of US$51.0 million revenue and a US$23.6 million loss.
• What stands out for the bullish narrative is that forecasts call for about 32.6% annual revenue growth and roughly 59.2% annual earnings growth, yet the latest trailing loss of US$133.2 million keeps profitability distant, so:
  • On the supportive side, bulls point to analysts expecting earnings to turn positive within three years while Q1 2026 EPS loss of US$0.47 is already smaller than the US$1.05 loss in Q2 2025.
  • In terms of tension, the company has recorded widening losses over the past five years at about 6.5% per year, which means the path from US$133.2 million of trailing losses to positive earnings still relies heavily on future execution.

Bulls argue this revenue base and shrinking quarterly EPS loss are early steps toward the growth story they expect, while the five year loss trend shows how much still has to change for that view to fully play out. 🐂 UroGen Pharma Bull Case

Still Loss Making With Balance Sheet Pressure

• Across the last five reported quarters, quarterly net losses ranged from US$23.6 million in Q1 2026 to US$49.9 million in Q2 2025, and risk indicators now flag less than one year of cash runway along with negative shareholders’ equity.
• Bears focus on this combination of persistent losses and balance sheet strain, arguing it could limit how long UroGen can support the current cost base, because:
  • Critics highlight that trailing twelve month net income is a loss of US$133.2 million and that losses have grown at about 6.5% annually over five years, which lines up with concerns about extended unprofitability.
  • They also point to the flagged cash runway under one year and negative equity as signs that further external funding may be needed if operating performance does not change meaningfully.

Skeptics warn that these ongoing losses and balance sheet risks could matter more to future returns than any one strong revenue print. 🐻 UroGen Pharma Bear Case

Valuation Gap Versus DCF Fair Value

• At a current share price of US$26.25, the stock is described as trading about 89.4% below a DCF fair value estimate of roughly US$247.58 and also at a P/S of 9.1x versus 11.4x for peers and 10.8x for the US biotechs industry.
• Consensus style narratives use this gap as part of a relative value argument, yet the trailing loss profile tempers how clean that signal looks, since:
  • On the supportive side, trailing revenue of US$140.5 million and a P/S of 9.1x compare with higher peer and industry multiples, which fits with the idea that the stock is cheaper on sales than many biotech comparables.
  • Balancing that, the same dataset reports US$133.2 million of trailing losses and ongoing negative margins, so the market may be weighing the cheaper P/S and large DCF fair value gap against the cash runway and equity risks.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for UroGen Pharma on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both optimism and concern in these numbers is understandable, so move quickly from headline impressions to your own judgment by weighing the 3 key rewards and 2 important warning signs.

Explore Alternatives

UroGen Pharma is still reporting sizeable losses, pressured cash runway, and negative shareholders’ equity, so profitability and balance sheet strength remain key areas of concern.

If you want ideas that put financial resilience front and center, check out the solid balance sheet and fundamentals stocks screener (46 results) to find companies with sturdier foundations and potentially lower risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.